It is suggested that clarifying expression modes of m6A regulators is of great significance for forecasting anticancer immune responses, which could be a powerful tool to indicate the efficacy of immunotherapies, such as PD-L1 treatment in GBM patients (Figure 3C). The gene discussed is CD274; the disease is glioblastoma.